Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorexant) 25 and 50 mg was recently approved and is expected to launch in Japan in Q4 2024 Tokyo, Japan and Cambridge …